| Ticker | ANTX |
|---|---|
| ISIN | US0373261058 |
| Sector | Atención sanitaria |
| Mercado | NASDAQ |
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
AN2 Therapeutics, Inc. opera en el sector Healthcare, industria Biotechnology.